Scholar Rock Holding (SRRK) Long-Term Debt Repayments (2025 - 2026)
Scholar Rock Holding (SRRK) posted quarterly Long-Term Debt Repayments of $103.1 million for Q1 2026, up 303.83% year-over-year from $25.5 million in Q1 2025, and up 303.83% quarter-over-quarter from $25.5 million in Q1 2025.
Powered by 
Analysis
Scholar Rock Holding (SRRK) Long-Term Debt Repayments (2025 - 2026) Analysis & Trends
Scholar Rock Holding's Long-Term Debt Repayments history runs 2 years deep, the most recent figure standing at $103.1 million for Q1 2026.
- In Q1 2026, Long-Term Debt Repayments rose 303.83% year-over-year to $103.1 million; the TTM figure through Mar 2026 stood at $103.1 million (changed N/A YoY), while the FY2025 annual figure was $25.5 million, changed N/A from the prior year.
- Long-Term Debt Repayments for Q1 2026 stood at $103.1 million, up from $25.5 million in the prior quarter.
- The five-year high for Long-Term Debt Repayments was $103.1 million in Q1 2026, with the low at $25.5 million in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 17.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Scholar Rock Holding | 7.24 Bn | 7.24 Bn | - | - |